



CRISPR/Cas9 genome editing in rodents : *In vivo* and *in vitro* applications

Birling MC¹, André P¹, Jacquot S¹, Schaeffer L¹, Marie Wattenhofer-Donze, Pavlovic G¹ and Hérault Y^{1,2}
¹Institut Clinique de la Souris, PHENOMIN, CNRS UMR7104, INSERM U964, Université de Strasbourg, 1 rue Laurent Fries BP 10142 Parc d'Innovation 67404 Illkirch, France
²Institut de Génétique Biologie Moléculaire et Cellulaire (IGBMC), CNRS, INSERM, Université de Strasbourg, UMR7104, UMR964, Illkirch, France

Introduction : The iCS is producing more than 150 new mouse lines per year and most of them are generated by conventional homologous recombination in ES cells (a well defined and very efficient workflow). Most of these lines are 'à la carte' targeted mutant. Different projects have been undertaken in the last 2 years using nucleases (ZFN, TALE and CRISPR/Cas). We describe here some of our CRISPR/Cas projects (*in vivo* and *in vitro* approaches)


1. Generation of Khl15 KO using CRISPR/cas approach

- Microinjection guides and Cas9 mRNAs into the pronucleus of C57Bl/6N fertilized eggs
- Founders with double stand breaks (DSB) are often mosaic (up to 4 different alleles observed in F1 mice)
- Frequency of DSB increased with the mRNA concentration
- KO to be confirmed by Western blot



2. The best strategy to obtain KO (quick and efficient)


- Microinjection in C57Bl/6N fertilized oocytes
- Deletion of one or more 'critical' exon (generation of a frame shift and premature STOP codon)



3. Correction of the Crb1^{rd8} in C57Bl/6N Mice

- Fertilized C57Bl/6N oocytes were co-injected with one or 2 guide RNAs, Cas9 mRNAs and a ssODN bearing the desired mutation plus 3 silent diagnostic mutations.
- Different injection conditions were tested
- Homology-directed repair was observed in 3.5% (2/57) of live-born animals and showed minimal illegitimate recombination of donor DNA.
- Extensive founder mosaicism was observed, emphasizing the need to analyze founder's offsprings.
- Two founders carried the corrected allele, but they also carried a secondary nearby mutation in Crb1 nullifying the functional rd8 correction (as observed in Low et al (2014) Invest Ophthalmol Vis Sci.2014;55:387-395 and and previous *in house* experiments with TALE nucleases).



Founders genotyping results after PCR subcloning and sequencing







4. Knock-in of a 6.9 kb transgene into the Rosa26 locus using CRISPR/Cas

Collaboration with Romeo Ricci's lab (IGBMC, Illkirch, France),

- Microinjection in C57Bl/6N fertilized oocytes
- High frequency of NHEJ events
- Low frequency of homologous recombination (1.1%)
- Efficiency of HR varies between microinjectionists
- Germ line transmission achieved




5. The use of CRISPR/Cas for big genomic rearrangements in rat



6. CRISPR/Cas highly improves homologous recombination *in vitro* in ES Cells

- Co-electroporation of a standard targeting vector and a vector expressing a specific guide RNA and the Cas9 dramatically improves the homologous recombination efficiency
- We managed to rescue 100% of the unsuccessful project
- Insertion of supplementary copies (concatemers) has been observed at the locus (see 4.) when a circular targeting construct is electroporated



Conclusion : The CRISPR/Cas technology is a powerful tool for the generation of genetically engineered rodents. The generation of KO lines is straight forward, deletions and duplications work well. The efficiency for the generation of complicated alleles (ie Knock-In) needs still to be improved and off-targets events need to be assessed.